Healthcare | May 23, 2022
Launch of joint research to collect a year’s worth of lifestyle data through wearable tracking device
Objective tracking data combined with cohort data to drive medicine of the future
Objective tracking data combined with cohort data to drive medicine of the future
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
Subscribe To Our Newsletter & Stay Updated
